2007
Nijmegen breakage syndrome 1 (NBS1) gene polymorphism and chemotherapy-induced neutropenic fever in breast cancer patients
Sun A, Yu T, Wang L, Lu J, Gonzales G, Pusztai L, Singletary S, Ross M, Wei Q, Buchholz T. Nijmegen breakage syndrome 1 (NBS1) gene polymorphism and chemotherapy-induced neutropenic fever in breast cancer patients. Journal Of Clinical Oncology 2007, 25: 574-574. DOI: 10.1200/jco.2007.25.18_suppl.574.Peer-Reviewed Original ResearchBreast cancer patientsAbsolute neutrophil countChemotherapy-induced neutropenic feverNeutropenic feverCancer patientsC polymorphismChemotherapy-induced bone marrow toxicityGene polymorphismsMultivariable logistical regression analysisMultivariable logistic regression modelGrowth factor supportPolymerase chain reaction-restriction fragment length polymorphism methodBone marrow toxicityTwo-sided ChiFragment length polymorphism methodGrowth factor useLogistical regression analysisLength polymorphism methodLogistic regression modelsInstitutional review boardNBS1 geneSystemic chemotherapyNeutrophil countChemotherapy administrationFactor support
1998
Daily Oral Etoposide in Patients With Heavily Pretreated Metastatic Breast Cancer
Pusztai L, Walters R, Valero V, Theriault R, Hortobagyi G. Daily Oral Etoposide in Patients With Heavily Pretreated Metastatic Breast Cancer. American Journal Of Clinical Oncology 1998, 21: 442-446. PMID: 9781596, DOI: 10.1097/00000421-199810000-00004.Peer-Reviewed Original ResearchConceptsGrade 4 toxicityMetastatic breast cancerSignificant hematologic toxicityOral etoposideBreast cancerGrade 2Hematologic toxicityDaily oral etoposideFourth-line agentZubrod performance statusPercent of patientsPhase II studyMajority of patientsGreater thrombocytopeniaNeutropenic feverStable diseasePrevious therapyRadiologic evidenceII studyMedian durationPartial responsePerformance statusMedian ageMore regimensSevere anemia